MX355944B - Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. - Google Patents
Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.Info
- Publication number
- MX355944B MX355944B MX2014011048A MX2014011048A MX355944B MX 355944 B MX355944 B MX 355944B MX 2014011048 A MX2014011048 A MX 2014011048A MX 2014011048 A MX2014011048 A MX 2014011048A MX 355944 B MX355944 B MX 355944B
- Authority
- MX
- Mexico
- Prior art keywords
- histidine
- human animals
- immunoglobulin
- germline
- codon
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 5
- 102000018358 immunoglobulin Human genes 0.000 title abstract 5
- 241001465754 Metazoa Species 0.000 title abstract 4
- 235000014304 histidine Nutrition 0.000 abstract 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 4
- 108020004705 Codon Proteins 0.000 abstract 3
- 210000004602 germ cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 150000002411 histidines Chemical class 0.000 abstract 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a animales no humanos genéticamente modificados que expresan un dominio variable de inmunoglobulina que comprende al menos una histidina, en donde la al menos una histidina es codificada por una sustitución de un codón no codificador de histidina de la línea germinal del animal, por un codón de histidina, o la inserción de un codón de histidina en una secuencia de ácido nucleico de inmunoglobulina de la línea germinal. También se proporcionan genes de inmunoglobulina que comprenden histidinas en una o más CDRs, en una región N-terminal, y/o en una región de asa 4. También se proporcionan dominios variables de inmunoglobulina que comprenden una o más histidinas (p. ej., agrupaciones de histidinas) sustituidas por residuos no histidina que no se unen al antígeno. También se proporcionan animales no humanos que son progenie de los animales que comprenden loci variables de cadena pesada modificados (segmentos V, D, J), loci variables de cadena ligera modificados (segmentos V, J), y genes de cadena ligera de línea germinal rearreglados (secuencias VJ). Se proporcionan animales no humanos que producen dominios de inmunoglobulina que se unen a antígenos de manera sensible al pH.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611950P | 2012-03-16 | 2012-03-16 | |
US201261612126P | 2012-03-16 | 2012-03-16 | |
US201261613352P | 2012-03-20 | 2012-03-20 | |
US201261736930P | 2012-12-13 | 2012-12-13 | |
PCT/US2013/032036 WO2013138712A1 (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014011048A MX2014011048A (es) | 2015-04-10 |
MX355944B true MX355944B (es) | 2018-05-07 |
Family
ID=48045752
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011048A MX355944B (es) | 2012-03-16 | 2013-03-15 | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. |
MX2021000484A MX2021000484A (es) | 2012-03-16 | 2014-09-12 | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000484A MX2021000484A (es) | 2012-03-16 | 2014-09-12 | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. |
Country Status (24)
Country | Link |
---|---|
US (4) | US9801362B2 (es) |
EP (2) | EP3539374A1 (es) |
JP (4) | JP6228589B2 (es) |
KR (3) | KR102345232B1 (es) |
CN (2) | CN104302171B (es) |
BR (1) | BR112014022855A2 (es) |
CA (1) | CA2865645A1 (es) |
CY (1) | CY1121864T1 (es) |
DK (1) | DK2825037T3 (es) |
ES (1) | ES2737990T3 (es) |
HK (1) | HK1200270A1 (es) |
HR (1) | HRP20191333T1 (es) |
HU (1) | HUE045537T2 (es) |
IL (4) | IL234237B (es) |
LT (1) | LT2825037T (es) |
MX (2) | MX355944B (es) |
NZ (3) | NZ629077A (es) |
PL (1) | PL2825037T4 (es) |
PT (1) | PT2825037T (es) |
RS (1) | RS59076B1 (es) |
RU (2) | RU2664473C2 (es) |
SG (3) | SG10202107388VA (es) |
SI (1) | SI2825037T1 (es) |
WO (1) | WO2013138712A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
KR20140100532A (ko) | 2011-11-30 | 2014-08-14 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약 |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
BR112014022855A2 (pt) | 2012-03-16 | 2017-07-18 | Regeneron Pharma | animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano |
RU2644684C2 (ru) | 2012-03-16 | 2018-02-13 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
MX2014011047A (es) * | 2012-03-16 | 2015-04-08 | Regeneron Pharma | Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph. |
MX363213B (es) * | 2012-08-13 | 2019-03-15 | Regeneron Pharma | Anticuerpos anti-pcsk9 con características de unión dependientes del ph. |
EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
MY185881A (en) * | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
PL3233921T3 (pl) | 2014-12-19 | 2022-01-10 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciała anty-c5 i sposoby ich stosowania |
TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
JP2018511557A (ja) * | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | 2種以上の抗c5抗体の組み合わせおよび使用方法 |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
JP2018508224A (ja) * | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
EP3291836A4 (en) | 2015-05-06 | 2018-11-14 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
CA3011359A1 (en) * | 2016-01-13 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
RU2745563C2 (ru) | 2016-05-20 | 2021-03-29 | Регенерон Фармасьютикалс, Инк. | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк |
KR102598120B1 (ko) | 2016-06-03 | 2023-11-07 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
WO2019098212A1 (en) | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
CN116874591A (zh) | 2018-03-24 | 2023-10-13 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途 |
IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
MA52175A (fr) | 2018-03-26 | 2021-02-17 | Regeneron Pharma | Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène |
CN108486126A (zh) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在人源化抗体中的应用 |
WO2019238686A1 (en) | 2018-06-13 | 2019-12-19 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | Peptides having inhibitory activity on muscarinic receptor m3 |
SG11202012084WA (en) | 2018-06-14 | 2021-01-28 | Regeneron Pharma | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
TW202229328A (zh) | 2020-09-11 | 2022-08-01 | 美商再生元醫藥公司 | 抗原特異性抗體之鑑定及產生 |
KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
US20240317849A1 (en) | 2020-12-23 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2024056044A1 (en) * | 2022-09-16 | 2024-03-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals and methods for producing heavy-chain antibodies |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
CA2075927A1 (en) | 1990-02-16 | 1991-08-17 | Victor A. Raso | Hybrid reagents capable of selectively releasing molecules into cells |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5999908A (en) | 1992-08-06 | 1999-12-07 | Abelow; Daniel H. | Customer-based product design module |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU718138B2 (en) | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
JP2007312792A (ja) | 1995-08-29 | 2007-12-06 | Kirin Pharma Co Ltd | キメラ動物およびその作製法 |
TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
ES2293691T3 (es) | 1997-10-03 | 2008-03-16 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humano natural. |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
ATE348883T1 (de) | 2000-09-08 | 2007-01-15 | Massachusetts Inst Technology | Zusammensetzungen und verfahren mit analogen von g-csf |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2003031656A1 (en) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
ES2645698T3 (es) | 2001-11-30 | 2017-12-07 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
CA2489022C (en) | 2002-06-12 | 2012-10-16 | Genencor International, Inc. | Methods for improving a binding characteristic of a molecule |
AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
JP4477579B2 (ja) | 2003-01-21 | 2010-06-09 | 中外製薬株式会社 | 抗体の軽鎖スクリーニング方法 |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
JP2007537704A (ja) | 2003-07-15 | 2007-12-27 | セラピューティック ヒューマン ポリクローナルズ, インコーポレイテッド | ヒト化免疫グロブリン遺伝子座 |
CN1560081A (zh) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链-κ轻链小鼠作为制备人源化单克隆抗体和应用 |
US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
RU2401842C2 (ru) * | 2004-10-08 | 2010-10-20 | Домантис Лимитед | Антагонисты и способы их применения |
PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
AU2005333602B2 (en) | 2004-10-22 | 2012-04-12 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
RU2290442C2 (ru) * | 2005-03-21 | 2006-12-27 | Всероссийский государственный научно-исследовательский институт животноводства (ВИЖ) | Способ трансформации стволовых клеток семенников животных in vivo |
PT2586459T (pt) * | 2005-03-25 | 2017-07-25 | Regeneron Pharma | Formulações antagonistas de fcev |
AU2006242854A1 (en) | 2005-04-29 | 2006-11-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Transgenic animals and methods of making recombinant antibodies |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2086998B1 (en) * | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
WO2008112922A2 (en) | 2007-03-13 | 2008-09-18 | National Jewish Medical And Research Center | Methods for generation of antibodies |
ITMI20071522A1 (it) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
KR101856210B1 (ko) * | 2007-10-26 | 2018-05-09 | 오클라호마 메디컬 리써치 화운데이션 | 활성 및 비활성 단백질 c에 대한 모노클로날 항체 |
CA3102704A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
EP2271762B1 (en) * | 2008-03-14 | 2016-12-07 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
DK2708559T3 (en) * | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
PT2147594E (pt) | 2008-06-27 | 2014-02-17 | Merus B V | Mamíferos não humanos que produzem anticorpos |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
LT2346994T (lt) * | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
WO2010128897A1 (en) | 2009-05-07 | 2010-11-11 | Volvo Construction Equipment Ab | A working machine and a method for operating a working machine |
DK2435568T3 (da) | 2009-05-29 | 2014-09-08 | Morphosys Ag | Samling af syntetiske antistoffer til behandling af sygdom |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
ES2658622T3 (es) | 2009-07-16 | 2018-03-12 | Wageningen Universiteit | Regulación de la deficiencia de zinc y tolerancia en plantas |
GB2472108B (en) | 2009-08-27 | 2011-07-13 | Budha Singh Dhinjan | Wall bead |
ES2595376T3 (es) | 2009-12-10 | 2016-12-29 | Regeneron Pharmaceuticals, Inc. | Ratones que producen anticuerpos de cadena pesada |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
RS55315B2 (sr) | 2010-02-08 | 2020-08-31 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
KR20120138241A (ko) | 2010-03-11 | 2012-12-24 | 화이자 인코포레이티드 | pH 의존성 항원 결합을 갖는 항체 |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN103228130B (zh) | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
BR112012032991B1 (pt) | 2010-06-22 | 2021-08-10 | Regeneron Pharmaceuticals, Inc | Método para preparar um anticorpo que se liga a um antígeno de interesse |
PL2738259T3 (pl) | 2011-02-25 | 2020-08-24 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
PT2739740T (pt) | 2011-08-05 | 2020-01-09 | Regeneron Pharma | Cadeia leve universal humanizada de murganhos |
SG11201401102VA (en) | 2011-09-30 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
KR20140136462A (ko) | 2012-03-06 | 2014-11-28 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄 마우스 |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
BR112014022855A2 (pt) | 2012-03-16 | 2017-07-18 | Regeneron Pharma | animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano |
RU2644684C2 (ru) | 2012-03-16 | 2018-02-13 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
MX2014011047A (es) | 2012-03-16 | 2015-04-08 | Regeneron Pharma | Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph. |
WO2013184761A1 (en) | 2012-06-05 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
JP6314142B2 (ja) | 2012-09-21 | 2018-04-18 | レオキシン ディスカバリーズ グループ,インコーポレイテッド | 液体を電気分解するためのセル |
MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2013
- 2013-03-15 BR BR112014022855A patent/BR112014022855A2/pt not_active Application Discontinuation
- 2013-03-15 EP EP19156973.0A patent/EP3539374A1/en active Pending
- 2013-03-15 CN CN201380025818.2A patent/CN104302171B/zh active Active
- 2013-03-15 ES ES13714127T patent/ES2737990T3/es active Active
- 2013-03-15 SG SG10202107388VA patent/SG10202107388VA/en unknown
- 2013-03-15 PT PT13714127T patent/PT2825037T/pt unknown
- 2013-03-15 SG SG10201700360VA patent/SG10201700360VA/en unknown
- 2013-03-15 RS RS20190989A patent/RS59076B1/sr unknown
- 2013-03-15 HU HUE13714127A patent/HUE045537T2/hu unknown
- 2013-03-15 WO PCT/US2013/032036 patent/WO2013138712A1/en active Application Filing
- 2013-03-15 CN CN201710192722.5A patent/CN107361011B/zh active Active
- 2013-03-15 DK DK13714127.1T patent/DK2825037T3/da active
- 2013-03-15 KR KR1020217003301A patent/KR102345232B1/ko active IP Right Grant
- 2013-03-15 NZ NZ629077A patent/NZ629077A/en not_active IP Right Cessation
- 2013-03-15 CA CA2865645A patent/CA2865645A1/en active Pending
- 2013-03-15 KR KR1020217042563A patent/KR102459666B1/ko active IP Right Grant
- 2013-03-15 EP EP13714127.1A patent/EP2825037B1/en active Active
- 2013-03-15 MX MX2014011048A patent/MX355944B/es active IP Right Grant
- 2013-03-15 NZ NZ712508A patent/NZ712508A/en not_active IP Right Cessation
- 2013-03-15 SI SI201331533T patent/SI2825037T1/sl unknown
- 2013-03-15 JP JP2015500651A patent/JP6228589B2/ja active Active
- 2013-03-15 RU RU2014141307A patent/RU2664473C2/ru not_active IP Right Cessation
- 2013-03-15 RU RU2018128915A patent/RU2018128915A/ru not_active Application Discontinuation
- 2013-03-15 NZ NZ730271A patent/NZ730271A/en not_active IP Right Cessation
- 2013-03-15 PL PL13714127T patent/PL2825037T4/pl unknown
- 2013-03-15 US US13/834,129 patent/US9801362B2/en active Active
- 2013-03-15 KR KR1020147025405A patent/KR102213535B1/ko active IP Right Grant
- 2013-03-15 LT LTEP13714127.1T patent/LT2825037T/lt unknown
- 2013-03-15 SG SG11201405171WA patent/SG11201405171WA/en unknown
- 2013-11-20 US US14/085,424 patent/US9648856B2/en active Active
-
2014
- 2014-08-21 IL IL234237A patent/IL234237B/en active IP Right Grant
- 2014-09-12 MX MX2021000484A patent/MX2021000484A/es unknown
-
2015
- 2015-01-29 HK HK15101009.0A patent/HK1200270A1/xx unknown
-
2016
- 2016-02-10 IL IL244098A patent/IL244098B/en active IP Right Grant
-
2017
- 2017-05-10 JP JP2017093832A patent/JP6574811B2/ja active Active
- 2017-09-13 US US15/703,490 patent/US11224207B2/en active Active
-
2018
- 2018-08-02 JP JP2018145734A patent/JP7011549B2/ja active Active
-
2019
- 2019-01-21 IL IL264362A patent/IL264362B/en active IP Right Grant
- 2019-07-23 HR HRP20191333TT patent/HRP20191333T1/hr unknown
- 2019-08-01 CY CY20191100821T patent/CY1121864T1/el unknown
-
2020
- 2020-04-27 IL IL274268A patent/IL274268B/en unknown
- 2020-10-16 JP JP2020174432A patent/JP2021007409A/ja active Pending
-
2021
- 2021-12-08 US US17/545,099 patent/US20220217955A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000484A (es) | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. | |
MY185881A (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
WO2015143414A3 (en) | Non-human animals that make single domain binding proteins | |
CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
MX355732B (es) | Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos. | |
MX2023001793A (es) | Ratones que producen proteinas de union que comprenden dominios vl. | |
MX2021014818A (es) | Anticuerpos monoclonales anti-cd303. | |
MX2021001074A (es) | Ratones de cadena ligera universal humanizados. | |
CY1121798T1 (el) | Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα ζωα πλην του ανθρωπου για τη δημιουργια αυτων | |
NZ734504A (en) | Humanized rodents that express heavy chains containing vl domains | |
IN2014DN08163A (es) | ||
EP4345163A3 (en) | Genetic engineering of non-human animals for the production of chimeric antibodies | |
WO2010036976A3 (en) | Novel vectors for production of antibodies | |
TH166794A (th) | สัตว์ที่ไม่ใช่มนุษย์ที่เป็นแบบฮิมแมไนซ์ที่มีโลคัสที่จำกัดของสายหนักของอิมมูโนโกลบูลิน | |
TH173398A (th) | หนูเมาส์ซึ่งแสดงออกเรเพอร์ทอร์ที่จำกัดของสายเบาของอิมมูโนโกลบูลิน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |